antiviral drugs

Paxlovid, the most widely prescribed drug to treat symptomatic COVID-19, has lately attracted a number of detractors.

An important drug from a giant drug company is bound to have a target on its back. Lately, this has been the case with Pfizer's Paxlovid.

Decades ago, a case report (relating the experience with a single patient) was published, which described how a person’s flu symptoms improved after a bowl of chicken soup, but then reappeared. The article was meant as a kind of parody of the

Pre-exposure prophylaxis (PrEP) is one of several historic breakthroughs in the four-decade battle against HIV/AIDS.

A recent, scary article in the Boston Globe proclaimed the following:

About two months ago, when Pfizer's Paxlovid (1) was first distributed to a very select group of pharmacies throughout the US, you pretty much had to know the Pope (and perhaps his pharmacist) to get your hands the

During his State of the Union Address last week, President Biden announced a plan to make it easier for people to get access to the new antiviral drug Paxlovid.

The White House just announced a "test to treat" program that is an excellent, but not perfect, way of dealing with future COVID infections.

I recently wrote an article comparing the availability and use of the two newly approved anti-COVID drugs (1) Paxlovid and molnupiravir. Bottom line: Doctors and patients voted with their scripts.

The good news? There's a very effective antiviral drug called Paxlovid that will keep you alive and out of the hospital when/if omicron gets you, and a second drug, molnupiravir, which doesn't work as well, but can still be helpful. The bad news?